A JAK2 mutation is a change in the gene that can cause uncontrolled blood cell production. JAK2 mutations are linked to blood cancers and disorders like polycythemia vera and essential thrombocythemia ...

The JAK2 gene mutation discovery led to JAK inhibitors, transforming myelofibrosis treatment by targeting the JAK-STAT pathway. Four FDA-approved JAK inhibitors for myelofibrosis include Jakafi, ...

Essential thrombocythemia (ET) is a type of myeloproliferative neoplasm (MPN), a rare blood disorder that causes an increase in the number of blood cells. Some symptoms include headaches, dizziness, ...

Concurrent ET and WM in a patient highlights challenges in managing coexisting myeloproliferative and lymphoplasmacytic malignancies. Distinct genetic mutations in the patient suggest independent ...

Treatments based on genomic profiling can significantly extend survival for patients with advanced or rare cancer, but only ...

Clearance of driver mutations at day 30 after transplantation was associated with a reduced risk of relapse and better survival among patients with myelofibrosis, a German study showed. Disease-free ...

MPN-U patients exhibit lower platelet counts and higher venous thrombosis rates compared to ET, with thrombosis often occurring at atypical sites. Genetic analysis shows JAK2 mutations are more common ...